

**META HEALTH LIMITED**  
(Incorporated in the Republic of Singapore)  
(Company Registration No. 198804700N)

---

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 518,066,109 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY AT A RIGHTS ISSUE PRICE OF S\$0.0055 FOR EACH RIGHTS SHARE ON THE BASIS OF NINE (9) RIGHTS SHARES FOR EVERY TEN (10) EXISTING ORDINARY SHARES IN THE CAPITAL OF THE COMPANY HELD BY EACH SHAREHOLDER OF THE COMPANY AS AT THE RECORD DATE, FRACTIONAL ENTITLEMENTS TO BE DISREGARDED**

- **LODGEMENT OF OFFER INFORMATION STATEMENT AND DESPATCH AND DISSEMINATION OF DOCUMENTS OF THE RIGHTS ISSUE**
  - **ACCEPTANCE OF RIGHTS SHARES AND APPLICATION FOR EXCESS RIGHTS SHARES**
  - **TRADING OF NIL-PAID RIGHTS**
  - **INDICATIVE TIMETABLE OF KEY EVENTS**
- 

**1. INTRODUCTION**

- 1.1. The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”) refers to the Company’s announcements dated 8 August 2023, 11 September 2023, 12 September 2023 and 21 September 2023 (the “**Previous Announcements**”) in relation to the Rights Issue.
- 1.2. Unless otherwise defined, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the offer information statement dated 4 October 2023 in relation to the Rights Issue, which is electronically disseminated by the Company on 4 October 2023 (the “**Offer Information Statement**”).
- 1.3. The Board also refers to:
- (a) the Securities and Futures (Offers of Investments) (Temporary Exemption from Sections 277(1)(c) and 305B(1)(b)) Regulations 2020 (the “**Temporary Exemption Regulations**”);
  - (b) the guidelines on the Securities and Futures (Offers of Investments) (Temporary Exemption from Sections 277(1)(c) and 305B(1)(b)) Regulations 2020 (Guideline No.: SFA 13-G21) released by the Monetary Authority of Singapore (the “**Authority**”) on 6 May 2020 (the “**Guidelines**”); and
  - (c) the joint statements by the Authority, the Securities Industry Council and the Singapore Exchange Regulation Pte. Ltd. issued on 6 May 2020, 29 September 2020 and 29 June 2021 in relation to, among others, the extension of the temporary measures introduced to allow electronic dissemination of offer documents of rights issues through publication on SGXNet and the issuers’ corporate websites (instead of despatch in hardcopies) beyond 30 June 2021, which will be in place until revoked or amended (together with the Temporary Exemption Regulations and the Guidelines, the “**Electronic Dissemination Measures**”).

**2. LODGEMENT OF THE OFFER INFORMATION STATEMENT**

The Company wishes to announce that the Offer Information Statement, together with its accompanying documents, have been lodged today with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”), acting as agent on behalf of the Authority.

### 3. DESPATCH OF THE OIS NOTIFICATION LETTER AND ITS ACCOMPANYING DOCUMENTS

3.1. Pursuant to the Electronic Dissemination Measures, no printed copies of the Offer Information Statement will be despatched to Entitled Shareholders, Renounees and Purchasers. Instead, an electronic copy of the Offer Information Statement has been made available for viewing online in a Portable Document Format (PDF) at, and may be accessed, downloaded and printed from the following online locations (the “**Online Locations**”):

(a) the Company’s corporate website at the following URL:

<https://metahealth.sg/investor-relations/offer-information-statement/>

(b) the SGXNet announcement page at the following URL:

<https://www.sgx.com/securities/company-announcements>, type the name of the Company: “Meta Health Limited” in the box titled “Filter by Company/Security Name”. META HEALTH LIMITED will appear as a drop-down item below the filter box. Please select “REPL::Rights::Voluntary” announcement dated 4 October 2023. The Offer Information Statement can be accessed by clicking on the link under the section titled “Attachments” at the bottom of the page of the announcement dated 4 October 2023.

3.2. Printed copies of the notification letter (the “**OIS Notification Letter**”) specifying the Online Locations and containing, among others, instructions on how to access, view, download and print the electronic version of the Offer Information Statement will be despatched, together with the Application Form for Rights Shares and Excess Rights Shares (the “**ARE**”) and the relevant envelope, to Entitled Shareholders on or around 6 October 2023.

3.3. For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the offer of the Rights Shares under the Rights Issue is only made in Singapore and the Offer Information Statement, the OIS Notification Letter and the accompanying documents have not been and will not be despatched or disseminated to Foreign Shareholders whose registered addresses with The Central Depository (Pte) Limited (“**CDP**”) are outside Singapore. Accordingly, Foreign Shareholders will not be entitled to participate in the Rights Issue, and no purported acceptance or application for the Rights Shares by Foreign Shareholders will be valid.

### 4. REQUEST FOR THE OIS NOTIFICATION LETTER AND ITS ACCOMPANYING DOCUMENTS

4.1. Entitled Depositors who do not receive the OIS Notification Letter and/or the ARE may contact CDP via its hotline at +65 6535 7511 or via email at [asksgx@sgx.com](mailto:asksgx@sgx.com), on Mondays to Fridays from 8.30 a.m. to 5.00 p.m., during the period from the date the Rights Issue commences up to 5.00 p.m. on 20 October 2023 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

4.2. Purchasers who do not receive the OIS Notification Letter and/or the Application Form for Rights Shares (the “**ARS**”) may obtain a copy thereof from CDP during the period from the date the Rights Issue commences up to 5.00 p.m. on 20 October 2023 (or such other time(s) and/or date(s) as may be announced from time to time by or on behalf of the Company).

4.3. Entitled Shareholders and Purchasers are advised to take note of the operating hours of CDP when contacting them for assistance.

### 5. ACCEPTANCES OF PROVISIONAL ALLOTMENTS OF RIGHTS SHARES AND (IF APPLICABLE) APPLICATIONS FOR EXCESS RIGHTS SHARES

5.1. Acceptances of provisional allotments of Rights Shares and (if applicable) applications for Excess Rights Shares under the Rights Issue may be made by Entitled Depositors by way of

the ARE and/or Electronic Application(s) through the ATMs of the Participating Banks or the SGX Investor Portal at <https://investors.sgx.com>.

- 5.2. For CPFIS Members, SRS Investors and investors who hold Shares through finance companies and/or Depository Agents, acceptances of their provisional allotments of Rights Shares and (if applicable) applications for Excess Rights Shares must be done through their respective approved CPF agent banks with whom they hold their CPF Investment Accounts, their respective SRS Approved Banks with whom they hold their SRS accounts, and their respective finance companies and/or Depository Agents, respectively. Such investors are advised to provide their respective approved CPF agent banks with whom they hold their CPF Investment Accounts, their respective SRS Approved Banks with whom they hold their SRS accounts, and their respective finance companies and/or Depository Agents, as the case may be, with the appropriate instructions no later than the deadlines set by such intermediaries in order for the intermediaries to make the relevant acceptance(s) and (if applicable) application(s) on their behalf by the Closing Date. Acceptances and/or (if applicable) applications made directly by CPFIS Members, SRS Investors and investors who hold Shares through finance companies and/or Depository Agents through CDP, Electronic Applications through ATMs of the Participating Banks or through an Accepted Electronic Service, the Share Registrar and/or the Company will be rejected.
- 5.3. More information on the procedures for, and terms and conditions applicable to, acceptance, renunciation, splitting and sale of and payment for the provisional allotments of Rights Shares and application and payment for Excess Rights Shares are set out in the Offer Information Statement, the ARE and the ARS.

## 6. TRADING PERIOD FOR NIL-PAID RIGHTS

- 6.1. The trading period for the provisional allotments of Rights Shares (or the Nil-Paid Rights) on the SGX-ST will commence at 9.00 a.m. on 6 October 2023 and end at 5.00 p.m. on 16 October 2023 (or the Rights Trading Period). Entitled Depositors who sell their Nil-Paid Rights during the Rights Trading Period do not have to forward the ARE to the Purchasers as arrangements will be made by CDP for a separate ARS to be issued to the Purchasers. Purchasers should note that CDP will, for and on behalf of the Company, send the ARS, accompanied by the OIS Notification Letter and other relevant accompanying documents, **by ordinary post and at the Purchasers' own risk**, to their respective Singapore addresses as maintained in the records of CDP. For the avoidance of doubt, only Entitled Shareholders (and not Purchasers or Renounees) shall be entitled to apply for additional Rights Shares in excess of their provisional allotments of Rights Shares.
- 6.2. For practical reasons and in order to avoid any violation of the securities legislation applicable in jurisdictions other than Singapore, the Offer Information Statement, the OIS Notification Letter and the accompanying documents will not be despatched to Foreign Purchasers of the provisional allotments of Rights Shares whose registered addresses with CDP are outside Singapore. Foreign Purchasers are advised that their participation in the Rights Issue may be restricted or prohibited by the laws of the jurisdiction in which they are located or resident. Foreign Purchasers who wish to accept the provisional allotments of Rights Shares credited to their Securities Accounts should make the necessary arrangements with their Depository Agents or stockbrokers in Singapore.

## 7. INDICATIVE TIMETABLE OF KEY EVENTS

- 7.1. Entitled Shareholders, Renounees and Purchasers should take note of the following important dates and times relating to the Rights Issue. All dates and times referred to below are Singapore dates and times.

Lodgement of the Offer Information Statement with the SGX-ST and electronic dissemination of the Offer Information Statement via the SGX-ST's website and the Company's corporate website : 4 October 2023

Despatch of the OIS Notification Letter and the ARE to Entitled Shareholders	:	6 October 2023
Commencement of trading of Nil-Paid Rights	:	6 October 2023 from 9.00 a.m.
First date and time for acceptance of and payment for Rights Shares and application of and payment for Excess Rights Shares by Entitled Depositors	:	6 October 2023 from 9.00 a.m.
Last date and time for splitting and trading of Nil-Paid Rights	:	16 October 2023 at 5.00 p.m.
Last date and time for acceptance of and payment for Rights Shares and application of and payment for Excess Rights Shares by Entitled Depositors	:	20 October 2023 at 5.30 p.m. (9.30 p.m. for Electronic Applications through ATMs of the Participating Banks)
Last date and time for acceptance of and payment for Rights Shares by Renounees and Purchasers	:	20 October 2023 at 5.30 p.m. (9.30 p.m. for Electronic Applications through ATMs of the Participating Banks)
Expected date for allotment, issuance and crediting of Rights Shares	:	30 October 2023
Expected date for refund of unsuccessful or invalid applications (if made through CDP)	:	30 October 2023
Expected date for listing and commencement of trading of Rights Shares	:	30 October 2023

7.2. Pursuant to Rule 820(1) of the Catalist Rules, the Rights Issue cannot be withdrawn after the Shares have commenced ex-rights trading. The Shares have commenced ex-rights trading on 2 October 2023 from 9.00 a.m..

7.3. The above timetable is indicative only and is subject to change. As at the date of this announcement, the Company does not expect the above timetable to be modified. However, the Company may, with the approval of its Sponsor, the SGX-ST and/or CDP, modify the timetable, subject to any limitation under any applicable laws, rules or regulations. In that event, the Company will publicly announce the modifications to the timetable through an announcement to be posted via SGXNet on the SGX-ST's website at <http://www.sgx.com>.

**Note:**

- (1) This does not apply to CPFIS Members, SRS Investors and investors who hold Shares through a finance company and/or Depository Agent. CPFIS Members, SRS Investors and investors who hold Shares through a finance company and/or Depository Agent should refer to the section entitled "**Important Notice to (A) CPFIS Members, (B) SRS Investors and (C) Investors Who Hold Shares through Finance Companies and/or Depository Agents**" of the Offer Information Statement. Any acceptance and (if applicable) application made by these persons directly through CDP, Electronic Applications through ATMs of Participating Banks or through an Accepted Electronic Service, the Share Registrar and/or the Company will be rejected. Such persons, where applicable, will receive notification letter(s) from their respective approved CPF agent banks with whom they hold their CPF Investment Accounts, their respective SRS Approved Banks with whom they hold their SRS accounts, and their respective finance companies and/or Depository Agents, as the case may be, and should refer to such notification letter(s) for details of the last date and time to submit applications to their respective approved CPF agent banks with whom they hold their CPF Investment Accounts, their respective SRS Approved Banks with whom they hold their SRS accounts, and their respective finance companies and/or Depository Agents, as the case may be.

## 8. FURTHER ANNOUNCEMENTS

- 8.1. As soon as practicable after the Closing Date, the Company will announce the results of the Rights Issue through an announcement to be posted via SGXNet on the SGX-ST's website at <http://www.sgx.com>.
- 8.2. Further announcements on the Rights Issue will be made by the Company as and when appropriate.

## 9. IMPORTANT NOTICES

- 9.1. This announcement is qualified in its entirety by, and should be read in conjunction with, the full text of the Offer Information Statement.
- 9.2. Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares and the Rights Shares. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement, the Previous Announcements and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

## BY ORDER OF THE BOARD

**Lee Wei Hsiung**  
**Company Secretary**  
**4 October 2023**

---

*This announcement has been prepared by Meta Health Limited (the “Company”) and its contents have been reviewed by the Company’s sponsor, ZICO Capital Pte. Ltd. (the “Sponsor”), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (“SGX-ST”) Listing Manual Section B: Rules of Catalyst.*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Alex Tan, Chief Executive Officer, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.*